Health

STAT+: FDA adcomm members’ ties to industry under scrutiny

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 14/10/2026, 14:21:24 UTC.

Briefings

STAT+ reports on the death of infectious disease correspondent Helen Branswell and details a new GLP-1 trial in Pittsburgh testing drug effects on addiction and recidivism. The trial enrolls up to 1,200 adults with substance use disorders, with half receiving Novo Nordisk's Wegovy, scheduled for early 2027.

Key points

• Infectious disease correspondent Helen Branswell passed away, prompting a tribute from STAT+ staff.
• A new GLP-1 trial in Pittsburgh will test drug effects on addiction and recidivism among up to 1,200 adults.

Context

STAT+ covers infectious disease reporting and recent industry litigation settlements. The GLP-1 trial represents a new research initiative focused on addiction outcomes and social impact.

Limitations

Branswell's death is reported as a past event with no specific date provided. Trial details are preliminary, with enrollment capped at 1,200 and launch scheduled for early 2027.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 24/10/2026, 06:09:11 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeieoxy2w4yyuqrnmibm6ezoumsn4jbc677n36iif45z7r7tvq4s7mu